Small Molecule Cancer Drug Market
Global Small Molecule Cancer Drug Market Size, Share, and Trends Analysis Report, by Drug Class (Alkylating Agents, Plant Alkaloids, Antitumor Antibiotics, Antimetabolites, Topoisomerase Inhibitors, and Others), by Route of Administration (Oral and Injectable), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), Forecast Period (2022-2028)
The global small molecule cancer drug market is anticipated to grow at a considerable CAGR of 10.0% during the forecast period. The rising prevalence of cancer is the major factor behind the rising demand for small molecular drugs globally. The awareness programs initiated by governments across the globe for early diagnosis and treatment of cancer are also supporting the growth of the market. For instance, in November 2018, the European Commission announced the availability of the European Commission Initiative on Breast Cancer (ECIBC) recommendations about breast cancer imaging and diagnosis. The ECIBC develops the European breast guidelines, and evidence-based references to provide women and healthcare providers with bright, objective, and individualistic guidance on breast cancer diagnosis and treatment.
However, these drugs cure cancer very slowly and are effective in the treatment of the initial stage of cancer. Most cancer cases around the globe are diagnosed at later stages, due to which consumers prefer rapid-acting treatment options. Thus, alternate treatment options for cancer treatment will hamper the growth of the small molecule cancer drug market during the forecast period. This report will further analyze all the primary and secondary factors that are directly or indirectly influencing the growth of the small molecule cancer drug market during the forecast period.
Diagnosis and treatment of several patients with different disorders were postponed during the COVID-19 crisis as hospital beds were reserved for COVID-19 patients. Due to this reason the market players had reported a significant decline during the COVID-19 pandemic. However, as the situation got normalized the market had bounced back to its pre-COVID-19 pandemic level.
Segmental Outlook
The global small molecule cancer drug market is segmented based on the drug class, route of administration, and distribution channel. Based on the drug class, the market is segmented into alkylating agents, plant alkaloids, antitumor antibiotics, antimetabolites, topoisomerase inhibitors, and others. Based on the route of administration, the market is sub-segmented into oral and injectable. Among these routes of administration, the oral segment is expected to grow fastest during the forecast period.
Based on the distribution channel, the market is sub-segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Among these, distribution channels, the hospital pharmacies segment holds the major share in the market as these types of drugs are only consumed after the doctor’s prescription. However, the online pharmacies segment is expected to grow fastest during the forecast period due to the rising penetration of e-commerce globally.
Regional Outlooks
The global small molecule cancer drug market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). The market can also be analyzed for a particular region or country level as per the requirement.
Global Small Molecule Cancer Drug Market Growth by Region, 2022-2028
The North American Region Holds the Major Share in the Global Small Molecule Cancer Drug Market
The North American region holds the major share in the global small molecule cancer drug market due to significantly high healthcare spending. The US and Canada are the major contributing nation in this regional market. The US spends almost 17.7% of GDP on healthcare expenditure, whereas Canada spends 15.2% of GDP on healthcare as per Organisation for Economic Co-operation and Development (OECD, 2019). Moreover, the market is also growing due to the rising prevalence of cancer cases in this region. According to Globocan, 2.5 million new cancer cases were registered in this region in 2020 with 699.3 thousand mortalities caused. Prostate cancer was the most prevalent type of cancer with a share of 17.5% of the total new cancer cases registered in 2020.
Market Players Outlook
The major companies serving the global small molecule cancer drug market include Abbott Laboratories Inc., AstraZeneca Plc, Novartis AG, Pfizer Inc., SANOFI AVENTIS US LLC, Bayer HealthCare AG, GlaxoSmithKline PLC, and Boehringer Ingelheim GmbH, among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance-
• Servier collaborated and signed an exclusive license option agreement with PRISM BioLab in June 2021. PRISM BioLab provides PepMetics (peptide mimetic small molecules) technology for generating hit and lead compounds against Servier’s novel target.
• Iktos announced the application of Iktos Artificial Intelligence technology for de novo design to selected Pfizer small-molecule discovery programs in March 2021.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global small molecule cancer drug market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global Small Molecule Cancer Drug Market
• Recovery Scenario of Global Small Molecule Cancer Drug Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. AstraZeneca PLC
3.1.1.1. Overview
3.1.1.2. Financial Analysis
3.1.1.3. SWOT Analysis
3.1.1.4. Recent Developments
3.1.2. Novartis AG
3.1.2.1. Overview
3.1.2.2. Financial Analysis
3.1.2.3. SWOT Analysis
3.1.2.4. Recent Developments
3.1.3. Pfizer, Inc.
3.1.3.1. Overview
3.1.3.2. Financial Analysis
3.1.3.3. SWOT Analysis
3.1.3.4. Recent Developments
3.1.4. Sanofi SA
3.1.4.1. Overview
3.1.4.2. Financial Analysis
3.1.4.3. SWOT Analysis
3.1.4.4. Recent Developments
3.2. Key Strategy Analysis
4. Market Segmentation
4.1. Global Small Molecule Cancer Drug Market by Drug Class
4.1.1. Alkylating Agents
4.1.2. Plant Alkaloids
4.1.3. Antitumor Antibiotics
4.1.4. Antimetabolites
4.1.5. Topoisomerase Inhibitors
4.1.6. Others
4.2. Global Small Molecule Cancer Drug Market by Route of Administration
4.2.1. Oral
4.2.2. Injectable
4.3. Global Small Molecule Cancer Drug Market by Distribution Channel
4.3.1. Hospital Pharmacies
4.3.2. Retail Pharmacies
4.3.3. Online Pharmacies
5. Regional Analysis
5.1. North America
5.1.1. US
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Abbott Laboratories
6.2. Baxter Healthcare Corp.
6.3. Bayer HealthCare AG
6.4. Boehringer Ingelheim GmbH
6.5. Cytokinetics Inc.
6.6. Eli Lilly and Co.
6.7. Emcure Pharmaceuticals Ltd.
6.8. GlaxoSmithKline PLC
6.9. Hospira, Inc.
6.10. HQ Specialty Pharma Corp.
6.11. Janssen Research and Development LLC
6.12. Kyowa Kirin Inc.
6.13. OncoGenex Pharmaceuticals, Inc.
6.14. Otsuka Pharmaceutical Co. Ltd.
1. GLOBAL SMALL MOLECULE CANCER DRUG MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)
2. GLOBAL ALKYLATING AGENTS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL PLANT ALKALOIDS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL ANTITUMOR ANTIBIOTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL ANTIMETABOLITES MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL TOPOISOMERASE INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL OTHER DRUG CLASS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL SMALL MOLECULE CANCER DRUG MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
9. GLOBAL ORAL SMALL MOLECULE CANCER DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL INJECTABLE SMALL MOLECULE CANCER DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11. GLOBAL SMALL MOLECULE CANCER DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
12. GLOBAL SMALL MOLECULE CANCER DRUG BY HOSPITAL PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
13. GLOBAL SMALL MOLECULE CANCER DRUG BY RETAIL PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
14. GLOBAL SMALL MOLECULE CANCER DRUG BY ONLINE PHARMACIES MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
15. GLOBAL PANCREATIC SMALL MOLECULE CANCER DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
16. GLOBAL OVARIAN SMALL MOLECULE CANCER DRUG MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
17. GLOBAL OTHER SMALL MOLECULE CANCER DRUG MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
18. NORTH AMERICAN SMALL MOLECULE CANCER DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
19. NORTH AMERICAN SMALL MOLECULE CANCER DRUG MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)
20. NORTH AMERICAN SMALL MOLECULE CANCER DRUG MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
21. NORTH AMERICAN SMALL MOLECULE CANCER DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
22. EUROPEAN SMALL MOLECULE CANCER DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
23. EUROPEAN SMALL MOLECULE CANCER DRUG MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)
24. EUROPEAN SMALL MOLECULE CANCER DRUG MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
25. EUROPEAN SMALL MOLECULE CANCER DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
26. ASIA-PACIFIC SMALL MOLECULE CANCER DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
27. ASIA-PACIFIC SMALL MOLECULE CANCER DRUG MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)
28. ASIA-PACIFIC SMALL MOLECULE CANCER DRUG MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
29. ASIA-PACIFIC SMALL MOLECULE CANCER DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
30. REST OF THE WORLD SMALL MOLECULE CANCER DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
31. REST OF THE WORLD SMALL MOLECULE CANCER DRUG MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)
32. REST OF THE WORLD SMALL MOLECULE CANCER DRUG MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
33. REST OF THE WORLD SMALL MOLECULE CANCER DRUG MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
1. GLOBAL SMALL MOLECULE CANCER DRUG MARKET SHARE BY DRUG CLASS, 2021 VS 2028 (%)
2. GLOBAL ALKYLATING AGENTS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
3. GLOBAL PLANT ALKALOIDS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
4. GLOBAL ANTITUMOR ANTIBIOTICS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
5. GLOBAL ANTIMETABOLITES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL TOPOISOMERASE INHIBITORS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL OTHER DRUG CLASS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8. GLOBAL SMALL MOLECULE CANCER DRUG MARKET SHARE BY ROUTE OF ADMINISTRATION, 2021 VS 2028 (%)
9. GLOBAL ORAL SMALL MOLECULE CANCER DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. GLOBAL INJECTABLE SMALL MOLECULE CANCER DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
11. GLOBAL SMALL MOLECULE CANCER DRUG MARKET SHARE BY DISTRIBUTION CHANNEL, 2021 VS 2028 (%)
12. GLOBAL SMALL MOLECULE CANCER DRUG BY HOSPITAL PHARMACIES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL SMALL MOLECULE CANCER DRUG BY RETAIL PHARMACIES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
14. GLOBAL SMALL MOLECULE CANCER DRUG BY ONLINE PHARMACIES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
15. GLOBAL SMALL MOLECULE CANCER DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
16. US SMALL MOLECULE CANCER DRUG MARKET SIZE, 2021-2028 ($ MILLION)
17. CANADA SMALL MOLECULE CANCER DRUG MARKET SIZE, 2021-2028 ($ MILLION)
18. UK SMALL MOLECULE CANCER DRUG MARKET SIZE, 2021-2028 ($ MILLION)
19. FRANCE SMALL MOLECULE CANCER DRUG MARKET SIZE, 2021-2028 ($ MILLION)
20. GERMANY SMALL MOLECULE CANCER DRUG MARKET SIZE, 2021-2028 ($ MILLION)
21. ITALY SMALL MOLECULE CANCER DRUG MARKET SIZE, 2021-2028 ($ MILLION)
22. SPAIN SMALL MOLECULE CANCER DRUG MARKET SIZE, 2021-2028 ($ MILLION)
23. REST OF EUROPE SMALL MOLECULE CANCER DRUG MARKET SIZE, 2021-2028 ($ MILLION)
24. INDIA SMALL MOLECULE CANCER DRUG MARKET SIZE, 2021-2028 ($ MILLION)
25. CHINA SMALL MOLECULE CANCER DRUG MARKET SIZE, 2021-2028 ($ MILLION)
26. JAPAN SMALL MOLECULE CANCER DRUG MARKET SIZE, 2021-2028 ($ MILLION)
27. REST OF ASIA-PACIFIC SMALL MOLECULE CANCER DRUG MARKET SIZE, 2021-2028 ($ MILLION)
28. REST OF THE WORLD SMALL MOLECULE CANCER DRUG MARKET SIZE, 2021-2028 ($ MILLION)
